title: Anti-CD3 antibody MacroGenics Inc.
abstract: A non-FcR-binding anti-CD3 monoclonal antibody, hOKT3gamma1 (Ala-Ala), originally developed by Columbia University, is being developed by MacroGenics for the potential treatment of type 1 diabetes and autoimmune diseases. Phase I/II trials in patients with diabetes have been completed, and a phase II clinical trial in psoriatic arthritis was initiated in October 2005. A Phase II trial that will evaluate a multi-course study of the drug in patients with new-onset diabetes began in March 2006. MacroGenics is currently seeking to outlicense the project to a strategic partner.
authors.affiliation: Paddock Laboratories Inc, 3940 Quebec Avenue North, Minneapolis, MN 55427, USA. wbrown@paddocklabs.com
authors.forename: William M
authors.initials: WM
authors.lastname: Brown
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D016381:Islets of Langerhans Transplantation; D016030:Kidney Transplantation; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000096:biosynthesis / Q000627:therapeutic use*
chemical_list: D016853:Muromonab-CD3